SCHEMBL23927965

SCHEMBL23927965

O=C1C[C@H](CO)[C@@H](O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3900672 0.74
SCHEMBL3899974 0.74
SCHEMBL3310184 0.74
SCHEMBL1933577 0.73 BRD4 (0.33)
SCHEMBL1933580 0.73 BRD4 (0.33)
SCHEMBL1934068 0.73 BRD4 (0.33)
SCHEMBL1934066 0.73 BRD4 (0.33)
SCHEMBL1934262 0.73 BRD4 (0.33)
SCHEMBL10964532 0.73 MEN1 (0.41)
SCHEMBL3136461 0.69 MEN1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113784721-B High activity compounds against COVID-19 阿堤亚制药公司 2025-06-13 CN disclosed
CN-119139338-A High activity compounds against COVID-19 阿堤亚制药公司 2024-12-17 CN disclosed
CN-118948877-A High activity compounds against COVID-19 阿堤亚制药公司 2024-11-15 CN disclosed
US-11738038-B2 Highly active compounds against COVID-19 Atea Pharmaceuticals, Inc. (US) 2023-08-29 US disclosed
US-20220347200-A1 HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 Atea Pharmaceuticals, Inc. (US) 2022-11-03 US disclosed
CN-113784721-A High activity compound for resisting COVID-19 阿堤亚制药公司 2021-12-10 CN disclosed
EP-3897668-A1 HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 ATEA Pharmaceuticals, Inc. (US) 2021-10-27 EP disclosed